WO1989001973A3 - Virus variolique recombinant d'immunisation contre des antigenes associes a une tumeur - Google Patents

Virus variolique recombinant d'immunisation contre des antigenes associes a une tumeur Download PDF

Info

Publication number
WO1989001973A3
WO1989001973A3 PCT/US1988/003032 US8803032W WO8901973A3 WO 1989001973 A3 WO1989001973 A3 WO 1989001973A3 US 8803032 W US8803032 W US 8803032W WO 8901973 A3 WO8901973 A3 WO 8901973A3
Authority
WO
WIPO (PCT)
Prior art keywords
associated antigens
against tumor
pox virus
immunization against
recombinant pox
Prior art date
Application number
PCT/US1988/003032
Other languages
English (en)
Other versions
WO1989001973A2 (fr
Inventor
Dennis L Panicali
Rene Bernards
Original Assignee
Applied Biotechnology Inc
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Biotechnology Inc, Whitehead Biomedical Inst filed Critical Applied Biotechnology Inc
Publication of WO1989001973A2 publication Critical patent/WO1989001973A2/fr
Publication of WO1989001973A3 publication Critical patent/WO1989001973A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Virus varioliques recombinants capables d'exprimer des antigènes codés par des cellules, associés à une tumeur. Les virus recombinants sont utiles pour susciter une réaction immunitaire contre l'antigène.
PCT/US1988/003032 1987-09-02 1988-09-01 Virus variolique recombinant d'immunisation contre des antigenes associes a une tumeur WO1989001973A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9203687A 1987-09-02 1987-09-02
US092,036 1987-09-02

Publications (2)

Publication Number Publication Date
WO1989001973A2 WO1989001973A2 (fr) 1989-03-09
WO1989001973A3 true WO1989001973A3 (fr) 1989-03-23

Family

ID=22231039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/003032 WO1989001973A2 (fr) 1987-09-02 1988-09-01 Virus variolique recombinant d'immunisation contre des antigenes associes a une tumeur

Country Status (2)

Country Link
CA (1) CA1341435C (fr)
WO (1) WO1989001973A2 (fr)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US6241982B1 (en) 1988-03-21 2001-06-05 Chiron Corporation Method for treating brain cancer with a conditionally lethal gene
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
ATE174514T1 (de) * 1989-01-23 1999-01-15 Chiron Corp Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
DE69031120T2 (de) 1989-05-19 1998-01-15 Genentech Inc Her2 extrazellulare domäne
US7282345B1 (en) 1989-08-04 2007-10-16 Schering Ag C-erbB-2 external domain: GP75
EP0494135B1 (fr) * 1989-09-29 1996-04-10 Oncogene Science, Inc. Protéine humaine "neu" p100 et son utilisation pour la détection de cellules prénéoplasiques ou néoplasiques chez l'homme
ATE212672T1 (de) * 1989-10-24 2002-02-15 Chiron Corp System zur freisetzung von infektiösen proteinen
CA2040099A1 (fr) * 1990-05-01 1991-11-02 Mariano Barbacid Tyrosine-kinase-negative trkb
US5759552A (en) * 1991-03-07 1998-06-02 Virogenetics Corporation Marek's disease virus recombinant poxvirus vaccine
JP3399943B2 (ja) * 1991-05-06 2003-04-28 アメリカ合衆国 癌胎児性抗原を発現する組換えウイルスとその使用方法
US5545533A (en) * 1991-05-25 1996-08-13 Boehringer Mannheim Gmbh Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies
DE4205148A1 (de) * 1991-05-25 1993-01-21 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen c-kit
AU671971B2 (en) * 1991-11-29 1996-09-19 Chiron Corporation Anti-cancer immunotherapeutic vector constructs
WO1995014091A2 (fr) 1993-11-18 1995-05-26 Chiron Viagene, Inc. Compositions et procedes d'utilisation de genes a pouvoir letal conditionnel
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
AU2800797A (en) 1996-04-05 1997-10-29 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
AU3514197A (en) 1996-07-03 1998-01-21 Genetics Institute Inc. Protease fmh-1, an ice/ced-like protease
EP2298900A1 (fr) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions et procédés de traitement de maladies intracellulaires
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
ATE376062T1 (de) 1997-08-04 2007-11-15 Cell Genesys Inc Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
EP2386630A1 (fr) 1997-10-14 2011-11-16 Darwin Molecular Corporation Mutants de kinase de thymidine et protéines de fusion ayant de la kinase de thymidine et activités de kinase de guanylate
EP1900818A3 (fr) 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Antigènes de Neisserial
AU2010699A (en) 1997-12-24 1999-07-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for theiruse
CA2317815A1 (fr) 1998-01-14 1999-07-22 Chiron S.P.A. Antigenes du $i(neisseria meningitidis)
EP1792988A3 (fr) 1998-03-18 2007-08-22 Corixa Corporation Composés et méthodes thérapeutiques et diagnostiques du cancer du poumon
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP2261343A3 (fr) 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
PL346213A1 (en) 1998-08-07 2002-01-28 Univ Washington Immunological herpes simplex virus antigens and methods for use thereof
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
JP2002527066A (ja) 1998-10-15 2002-08-27 カイロン コーポレイション 転移性乳癌および結腸癌調節遺伝子
GB2370571B (en) * 1998-11-18 2003-05-07 Oxford Biomedica Ltd A modified 5t4 antigen
EP1036091B2 (fr) * 1998-11-18 2008-03-26 Oxford Biomedica (UK) Limited Antigene associe a la tumeur 5t4 pour une utilisation en immunotherapie anti-tumeur
US7148035B1 (en) 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
IL143531A0 (en) 1998-12-08 2002-04-21 Corixa Corp Polypeptides containing an antigenic portion of a chlamydia antigen, dna sequences encoding said polypeptides and pharmaceutical compositions and vaccines containing the same
EP1141331B1 (fr) 1998-12-16 2008-09-17 Novartis Vaccines and Diagnostics, Inc. KINASE DEPENDANT DE LA CYCLINE DE TYPE HUMAIN (hPNQALRE)
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
EP2028190A1 (fr) 1999-04-02 2009-02-25 Corixa Corporation Composés et procédés de thérapie et de diagnostic du cancer du poumon
DK1228217T3 (da) 1999-04-30 2013-02-25 Novartis Vaccines & Diagnostic Konserverede neisseria-antigener
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
ES2543736T3 (es) 1999-10-29 2015-08-21 Glaxosmithkline Biologicals Sa Péptidos antigénicos de Neisseria
DK2289545T3 (en) 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
KR20090085697A (ko) 2000-02-23 2009-08-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 종양 특이적 동물 단백질
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2001081379A2 (fr) 2000-04-21 2001-11-01 Corixa Corporation Composes et procedes pour le traitement et le diagnostic d'une infection a chlamydia
PT1284740E (pt) 2000-05-19 2008-07-09 Corixa Corp Tratamento profiláctico e terapêutico de doenças infecciosas, autoimunes e alérgicas com compostos à base de monossacáridos
EP1950297A2 (fr) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions et procédés de traitement de maladie néoplastique utilisant la chimiothérapie et des sensibilisateurs à rayonnement
ES2333579T3 (es) 2000-06-20 2010-02-24 Corixa Corporation Proteinas de fusion de mycobacterium tuberculosis.
DE60134158D1 (de) 2000-06-28 2008-07-03 Corixa Corp Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
US20020165192A1 (en) 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
US7691821B2 (en) 2001-09-19 2010-04-06 University Of South Florida Inhibition of SHIP to enhance stem cell harvest and transplantation
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP2706116A1 (fr) 2001-01-17 2014-03-12 Emergent Product Development Seattle, LLC Proteines de fusion d'immunoglobuline de domaine de liaison
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
DE60228758D1 (de) 2001-12-12 2008-10-16 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
ES2405790T3 (es) 2001-12-17 2013-06-03 Corixa Corporation Composiciones y métodos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
US20030206916A1 (en) 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
WO2004009021A2 (fr) 2002-07-18 2004-01-29 University Of Washington Purification rapide et efficace de t-lymphocytes specifiques au hsv et antigenes a hsv identifies par ce procede
DE60332477D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
ES2639812T3 (es) 2003-01-06 2017-10-30 Corixa Corporation Ciertos compuestos de fosfato de aminoalquil glucosaminida y sus usos
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2005007673A2 (fr) 2003-07-03 2005-01-27 Rush University Medical Center Peptides immunogenes
US7807646B1 (en) 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US7763592B1 (en) 2003-11-20 2010-07-27 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
KR101222281B1 (ko) 2004-03-29 2013-01-28 가르파마 컴퍼니 리미티드 신규 갈렉틴 9 개변체 단백질 및 그 용도
EP2848942B1 (fr) 2004-07-14 2017-03-08 The Regents of The University of California Biomarqueurs pour la détection précoce du cancer des ovaires
EP1789552A2 (fr) 2004-08-10 2007-05-30 Institute for Multiple Myeloma and Bone Cancer Research Procédés pour réguler la différenciation et traiter le myélome multiple
ES2540770T3 (es) 2004-09-22 2015-07-13 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
EP3312272B1 (fr) 2004-10-08 2019-08-28 The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services Modulation de la valeur d'adaptation réplicative par désoptimisation de codons synonymes
EP1701165A1 (fr) 2005-03-07 2006-09-13 Johannes Dr. Coy Utilisation thérapeutique et diagnostique de TKTL1, ses inhibiteurs et ses activateurs
US20090022755A1 (en) 2005-03-31 2009-01-22 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
PT2426141E (pt) 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
BRPI0613770A2 (pt) 2005-07-22 2009-05-19 Y S Therapeutics Co Ltd anticorpos anti-cd26 e métodos de uso destes
NI200800032A (es) 2005-07-25 2009-03-23 Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20
WO2007047749A1 (fr) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Immunisations mucosiques et systemiques avec particules de replicon d’alphavirus
CA2636424A1 (fr) 2006-01-09 2007-10-25 The Regents Of The University Of California Combinaisons immunostimulantes de tnfrsf, tlr, nlr, rhr, recepteurs purinergiques et d'agonistes des recepteurs de cytokines pour vaccins et immunotherapie contre les tumeurs
EP1981905B1 (fr) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccin contre chlamydia
US8524454B2 (en) 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
BRPI0716959A2 (pt) 2006-09-26 2013-10-29 Infectious Disease Res Inst Composição de vacina contendo adjuvante sintético
EP2139447A2 (fr) 2007-03-20 2010-01-06 Harold Brem Compositions gm-csf cosméceuticales et leurs procédés d'utilisation
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
WO2009126306A2 (fr) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions et procédés pour la détection des mutations d’egfr en cas de cancer
SI2132228T1 (sl) 2008-04-11 2011-10-28 Emergent Product Dev Seatle CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom
EP3124491B1 (fr) 2009-06-05 2019-10-30 Infectious Disease Research Institute Adjuvants lipidiques synthétiques à base de glucopyranosyle et compositions de vaccin ainsi que compositions pharmaceutiques les contenant
PL2528621T3 (pl) 2010-01-27 2017-07-31 Glaxosmithkline Biologicals S.A. Zmodyfikowane antygeny gruźlicy
EP3632463A1 (fr) 2011-04-08 2020-04-08 Immune Design Corp. Compositions immunogènes et leurs procédés d'utilisation pour induire des réponses immunitaires humorales et cellulaires
US9267112B2 (en) 2011-05-10 2016-02-23 The Regents Of The University Of California Adenovirus isolated from Titi Monkeys
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
WO2012177595A1 (fr) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions et méthodes pour la thérapie et le diagnostic du cancer
US9241976B2 (en) 2011-08-29 2016-01-26 The Regents Of The University Of California Use of HDL-related molecules to treat and prevent proinflammatory conditions
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
HUE044612T2 (hu) 2012-05-04 2019-11-28 Pfizer Prosztata-asszociált antigének és vakcina-alapú immunterápiás rendek
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
WO2014031178A1 (fr) 2012-08-24 2014-02-27 Etubics Corporation Vecteur adénoviral à réplication déficiente, utile en vaccination
WO2014144844A1 (fr) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Petits arn dérivés d'arnt (arnts) impliqués dans la viabilité cellulaire
WO2014144521A1 (fr) 2013-03-15 2014-09-18 The Regents Of The University Of California Peptide d'origine mitochondriale mots3 régule le métabolisme et la survie cellulaire
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US20160083698A1 (en) 2013-04-19 2016-03-24 The Regents Of The University Of California Lone star virus
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
AU2014284360B9 (en) 2013-07-01 2019-10-24 The Research Foundation For The State University Of New York Ship inhibition to combat obesity
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
AU2015280433B2 (en) 2014-06-17 2020-10-08 The Research Foundation For The State University Of New York Ship inhibition to induce expression of granulocyte colony stimulating factor in a subject
JP2017521654A (ja) 2014-06-27 2017-08-03 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ ヒトペギウイルス２（ＨＰｇＶ−２）を検出するための組成物および方法
EP3270897A4 (fr) 2015-03-20 2018-12-05 The Regents Of The University Of Michigan Compositions immunogènes pour une utilisation en vaccination contre les bordetella
WO2017053469A2 (fr) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Polypeptides de liaison à cd3
CN108431214B (zh) 2015-10-05 2022-03-01 美国政府(由卫生和人类服务部的部长所代表) 人轮状病毒g9p[6]毒株和作为疫苗的用途
BR112018013967A2 (pt) 2016-01-19 2019-02-05 Pfizer vacinas contra o câncer
JP7195148B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｔｌｒアゴニストを含有する製剤及び使用方法
WO2017210364A1 (fr) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoparticules d'alun contenant un agent d'encollage
CA3069363A1 (fr) 2017-07-11 2019-01-17 Pfizer Inc. Compositions immunogenes comprenant cea muc1 et tert
CN113896797B (zh) 2017-08-01 2023-05-09 Ab工作室有限公司 双特异性抗体及其用途
SG11202003443TA (en) 2017-11-24 2020-05-28 Eucure Beijing Biopharma Co Ltd Anti-ox40 antibodies and uses thereof
JP7448954B2 (ja) 2018-02-21 2024-03-13 ザ ユニバーシティー オブ モンタナ ジアリールトレハロース化合物及びその使用
JP7110369B2 (ja) 2018-02-23 2022-08-01 ユーキュア・（ベイジン）・バイオファーマ・カンパニー・リミテッド 抗ｐｄ－１抗体及びその用途
WO2019169313A1 (fr) 2018-03-02 2019-09-06 The University Of Montana Composés de tréhalose immunogènes et leurs utilisations
JP7212138B2 (ja) 2018-07-20 2023-01-24 ヨウキュア（ベイジン）バイオファーマ カンパニー リミテッド 抗ｃｄ４０抗体及びその使用
BR112021004698A2 (pt) 2018-09-12 2021-06-01 Eucure (Beijing) Biopharma Co., Ltd anticorpos anti-tnfrsf9 e usos dos mesmos
JP7469305B2 (ja) 2018-11-19 2024-04-16 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 抗ｐｄ－１抗体およびその使用
CA3138461A1 (fr) 2019-05-23 2020-11-26 Helene Bazin-Lee Adjuvants de vaccin a base de ligands du recepteur tlr

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188637A (en) * 1986-02-07 1987-10-07 Oncogen Vaccines against melanoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188637A (en) * 1986-02-07 1987-10-07 Oncogen Vaccines against melanoma

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
J. Gen. Virol. vol. 67, no. 10 (GB) M. Mackett et al.: "Review Article - Vaccinia virus expression vectors" pages 2067-2082 *
Nature, vol. 319, 16 January 1986, C.I. Bargmann et al.: "The neu oncogene encodes an epidermal growth factor receptor-related protein" pages 226-230 *
Nature, vol. 319, 16 January 1986, T. Yamamoto et al.: "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor" pages 230-234 *
Nature, vol. 319, 27 Februay 1986, D. Martin-Zanca et al.: "A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences" pages 743-748 *
Nature, vol. 326, 30 April 1987, R. Lathe et al.: "Tumour prevention and rejection with recombinant vaccinia" pages 878-880 *
Proc. Natl. Acad. Sci, USA, vol. 83, September 1986 (US) L. Nagarajan et al.: "The human c-ros gene (ROS) is located at chromosome region 6q16-6q22" pages 6568-6572 *
Proc. Natl. Acad. Sci, USA, vol. 84, October 1987 (US) R. Bernards et al.: "Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector" pages 6854-6858 *
The EMBO Journal, vol. 6, no. 11, (GB) Y. Yarden et al.: "Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand" pages 3341-3351 *

Also Published As

Publication number Publication date
CA1341435C (fr) 2003-07-29
WO1989001973A2 (fr) 1989-03-09

Similar Documents

Publication Publication Date Title
WO1989001973A3 (fr) Virus variolique recombinant d'immunisation contre des antigenes associes a une tumeur
CA2261989A1 (fr) Poxvirus recombinant pour l'immunisation contre des antigenes associes aux tumeurs
WO1995029193A3 (fr) Antigenes du melanome
EP1335023A3 (fr) Méthodes et réactifs pour induire une vaccination basée sur la production de cellules T CD8+
WO1993000365A3 (fr) Polypeptides utilises dans la lutte contre le virus de l'hepatite c
EP0904393A4 (fr) Vecteurs de parapoxvirus
EP2311952A3 (fr) Anticorps dirigé vers MART-1 protéine et ses fragments
EP0332424A3 (fr) Anticorps chimériques, dirigés contre l'antigène humaine carcino-embryonique
AR243080A1 (es) Procedimiento para obtener un complejo inmunogenico entre proteinas antigenicas o peptidos con regiones hidrofobas y bisdesmosidos con regiones hidrofobas.
NO892251D0 (no) Fremgangsmaate ved fremstilling av kokkoidosevaksine ved rekombinante teknikker.
AU2445888A (en) Recombinant fowlpox virus, vectors for the expression of heterologous proteins and vaccines for poultry derived from this virus
NO912825L (no) Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper.
GB9209718D0 (en) Hcg-hlh receptor and hcg-hlh receptor-hch complex as antigens,antibodies thereto and contraceptive vaccine
CA2272338A1 (fr) Immunisation de nourrissons
CA2101463A1 (fr) Vaccins recombinants anti-adenovirus
IT1147844B (it) Antigene della malaria,procedimento per la sua preparazione e vaccino con esso ottenuto
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
CA2135630A1 (fr) Epitopes de proteines de vih immunologiquement homologues aux proteines de hla
EP0327000A3 (en) Gene fragments coding for the variable region of an anti-hiv antibody, chimeric anti-hiv antibodies expressed using the same, and process for their preparation
NZ238833A (en) Equine herpesvirus-4 gh or gc polypeptides, nucleic acids encoding them and vaccines therefrom
DK0431327T3 (da) Syntetisk vaccine til specifik induktion af cytotoksiske T-lymfocytter
NZ223980A (en) An aids-type virus vaccine comprising an antibody equivalent which recognises an epitope on a cd4 cell-marker
AU2370592A (en) Epitopes of the env protein of the hepatitis c virus
AU2911289A (en) Carcinoma-associated antigens, and antibodies which recognize these antigens
AU4803785A (en) Cross-reactive and protective epitopes of circumsporozoite proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE